Format

Send to

Choose Destination
Radiol Oncol. 2012 Sep;46(3):207-12. doi: 10.2478/v10019-012-0040-0. Epub 2012 Jul 24.

Cathepsin X in serum from patients with colorectal cancer: relation to prognosis.

Author information

1
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

Abstract

BACKGROUND:

Up-regulation of lysosomal cysteine protease cathepsin X (Cat X) is associated with disorders of the immune system and neurodegenerative diseases, while its role in the development and progression of cancer is less understood. Enhanced secretion of pro-Cat X was observed in malignant processes, and therefore, the level of total serum Cat X rather than the active enzyme may better reflect the tumour status.

PATIENTS AND METHODS:

Seventy-seven patients with colorectal cancer (CRC) were included in a retrospective study. Blood samples were collected prior to therapy. Using ELISA, the values of total Cat X were measured in serum. Groups of healthy persons (n=77), patients with adenomas (n=77) and patients with non-neoplastic findings (n=77) were included.

RESULTS:

Significant differences between the group of colorectal patients and the groups of healthy persons, adenoma patients and patients with non-malignant findings could not be shown (p=0.89). Within the group of CRC, higher levels of total Cat X significantly correlated to shorter overall survival (HR=2.08, 95% CI:1.07-4.05, p=0.028).

CONCLUSIONS:

Total serum Cat X could be a useful prognostic indicator for determining survival of patients with CRC. Increased serum levels of total Cat X may reflect more aggressive tumour cell phenotypes and suggest the involvement of Cat X in processes involved in later stages of tumour progression.

KEYWORDS:

cathepsin X; colorectal cancer, prognosis; cysteine cathepsins; serum biomarker

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center